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Correspondence
Response to Letter Regarding Article, “Colchicine
Reduces Postoperative Atrial Fibrillation: Results
of the Colchicine for the Prevention of the
Postpericardiotomy Syndrome (COPPS) Atrial
Fibrillation Substudy”
We appreciate your interest in the COPPS postoperative atrial
fibrillation (POAF) substudy.1 Your letter has 2 main queries: The
time of colchicine administration, and the possible beneficial effects
of concomitant use of -blockers as a potential confounding factor in
the trial results.
The COPPS-POAF substudy is the first trial to test the hypothesis
that colchicine may be useful and safe for POAF prevention based on
preliminary findings regarding prevention of postpericardiotomy
syndrome by Finkelstein et al2 and evidence that anti-inflammatory
therapy, such as corticosteroids, may be beneficial for the prevention of
POAF.3 In the main trial (the COlchicine for the Prevention of the
Postpericardiotomy Syndrome [COPPS] trial), a recently published
prospective, randomized, double-blind, placebo-controlled multicenter
trial,4 colchicine was safe and efficacious for prevention of the postperi-
cardiotomy syndrome, halving its incidence at 12 months. The trial was
planned mainly to test the hypothesis of postpericardiotomy syndrome
prevention by colchicine, and the drug was given starting on postoper-
ative day 3 according to the preliminary experience of Finkelstein et al.2
On this basis, we were only able to test the efficacy and safety of
colchicine for POAF prevention from postoperative day 3 in the
COPPS-POAF substudy.1 A subsequent trial (the COPPS-2 trial;
ClinicalTrials.gov unique identifier: NCT01552187) has now started in
Italy to test the efficacy and safety of colchicine for prevention of the
postpericardiotomy syndrome and POAF when given 48 to 72 hours
before surgery, and results will be available at the end of 2012.
In the COPPS-POAF substudy, the concomitant use of -blockers
was evaluated and was found to be equally distributed in the
placebo/colchicine groups, as was the use of angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers. On this basis, we
are confident that colchicine efficacy was not related to the periop-
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